http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113929744-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3f30908fb44f111d0e0749e7792e7ee |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate | 2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0a6dd5a4028e5c3769c8bc70c5b24b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c907123bac1a492d69b679cd527adbbb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06ab84e22a381bb82faaaf2e2d00afc5 |
| publicationDate | 2022-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113929744-A |
| titleOfInvention | Abeta 42 fibroid-targeted peptoid and preparation method and application thereof |
| abstract | The invention relates to the technical field of biomedicine, and particularly discloses an Abeta 42 fibrous body-targeted peptoid and a preparation method and application thereof. The peptoids of the present invention include: a first subunit: cysteine, second subunit: 1, 4-butanediamine, third subunit: isobutylamine, fourth subunit: ethanolamine, fifth subunit: furfuryl amine, sixth subunit: isobutylamine and seventh subunit: 1, 4-butanediamine. The peptoid can be combined with a surface plasmon resonance imaging technology to detect Alzheimer disease or amnesia type mild cognitive impairment, and has the advantages of high specificity and strong sensitivity. In addition, the invention can directly detect the content of Abeta 42 fibrous bodies in blood without wound, can effectively distinguish AD patients from normal people by identifying the AD marker amyloid in serum, and provides a new liquid biopsy method and an idea for diagnosing and monitoring the progress of Alzheimer's disease or amnesic mild cognitive impairment and drug research and development. |
| priorityDate | 2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.